Technology

REGiMMUNE has a proprietary technology platform, reVax (reverse vaccination).
This is the only technology that can lead immuno-tolerance against specific antigen through induction of regulatory T cell (Treg) and is proven to be efficacious in various animals.

In some disorders like allergies and in autoimmune diseases such as Rheumatoid Arthritis (RA) and Multiple Sclerosis (MS), the immune system responds excessively or abnormally and may ultimately result in tissue destruction.

The reVax technology "re-educate" the immune system by inducing immune regulatory cells. In contrast to immunosuppressant which broadly downregulate immune system or typical vaccine therapy which enhance immunoprotective ability against an antigen by immunizing it with a specific adjuvant, this technology suppress immune system target specifically with keeping total immune reaction intact. In addition, reVax works not only as a vaccine in a prophylactic mode but also as a treatment mode.



To date, REGiMMUNE has developed two programs from its reVax technology: multivax and idiovax, and has another in early-stage development. Multivax is a compound containing a specific glycolipid that modulates the immune-regulating system. Idiovax is a reversibly acting vaccine containing a specific target antigen.

Based on its reVax technology, REGiMMUNE is developing two therapeutic compounds. The lead product candidate, RGI-1001, has demonstrated unique effects in preventing and treating allergic reaction, with no adverse impact on immunological response. An identified component activates Natural Killer T cells (NKT cells) by binding to the receptors of the targeted lymphocytes. The second product candidate is an allergen-loaded therapeutic agent that is antigen specific for certain target indications.

The REGiMMUNE vaccines in development have the potential to provide treatment for various allergic and immune diseases where there is a lack of effective therapies. Preclinical data suggest that the therapeutic agents deliver clinical benefits, with relatively short-term treatment course and without safety concerns. If proved effective in humans and commercialized, these vaccines may significantly affect the quality of life for millions of people worldwide.